Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Indoximod + Lomustine + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Indoximod | D-1MT|1-MT|NLG-8189 | IDO1 Inhibitor 13 | Indoximod (D-1MT) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases metabolism of tryptophan to kynurenine, potentially resulting in increased T-cell proliferation and activation and enhanced anti-tumor immune response (PMID: 17234791, PMID: 32637034, PMID: 34117113). | |
| Lomustine | Belustine | CCNU | ||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04049669 | Phase II | Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Recruiting | USA | 0 |